KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Accounts Payables (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Accounts Payables for 17 consecutive years, with $129.0 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 5.48% to $129.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $129.0 million through Dec 2025, up 5.48% year-over-year, with the annual reading at $129.0 million for FY2025, 5.48% up from the prior year.
  • Accounts Payables for Q4 2025 was $129.0 million at Bio-Rad Laboratories, roughly flat from $128.8 million in the prior quarter.
  • The five-year high for Accounts Payables was $161.0 million in Q1 2023, with the low at $102.8 million in Q1 2024.
  • Average Accounts Payables over 5 years is $136.1 million, with a median of $137.1 million recorded in 2021.
  • The sharpest move saw Accounts Payables crashed 36.17% in 2024, then surged 34.21% in 2025.
  • Over 5 years, Accounts Payables stood at $141.9 million in 2021, then dropped by 4.86% to $135.0 million in 2022, then rose by 7.08% to $144.6 million in 2023, then dropped by 15.42% to $122.3 million in 2024, then grew by 5.48% to $129.0 million in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $129.0 million, $128.8 million, and $139.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.